GE Healthcare and Vanderbilt University Medical Center (VUMC) announced a five-year partnership to enable safer and more precise cancer immunotherapies.    Multiple diagnostic tools will be developed to help predict both the efficacy of an immunotherapy treatment and its adverse effects for a specific patient before the therapy is administered. This would allow physicians to better target immunotherapies to the right patients and avoid potentially damaging, ineffective and costly courses...